Bisphosphonate use and gastrointestinal tract cancer risk: Meta-analysis of observational studies

World Journal of Gastroenterology

Volumn 18, Issue 40, 2012, Pages 5779-5788

  Oh, Yun Hwan ^a   Yoon, Chan ^a   Park, Sang Min ^a  

^a Seoul National University Hospital   (South Korea)

Author keywords

Bisphosphonate; Colorectal cancer; Esophageal cancer; Gastric cancer; Gastrointestinal tract cancer; Meta analysis

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

ARTICLE; CANCER RISK; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DISEASE ASSOCIATION; ESOPHAGUS CANCER; FOLLOW UP; HUMAN; INCIDENCE; META ANALYSIS; QUALITY CONTROL; SENSITIVITY ANALYSIS; STOMACH CANCER; TREATMENT OUTCOME;

BISPHOSPHONATE; COLORECTAL CANCER; ESOPHAGEAL CANCER; GASTRIC CANCER; GASTROINTESTINAL TRACT CANCER; META-ANALYSIS;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 84873924888     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i40.5779     Document Type: Article

References (24)

1. Green J, Lipton A. Anticancer properties of zoledronic acid. Cancer Invest 2010; 28: 944-957
2. Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 2004; 10: 4559-4567
3. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaissé JM, Clézardin P. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res 2000; 60: 2949-2954
4. Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C, Holen I, Mönkkönen H, Boccadoro M, Forni G, Musiani P, Bosia A, Cavallo F, Massaia M. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med 2010; 14: 2803-2815
5. Sato K, Kimura S, Segawa H, Yokota A, Matsumoto S, Kuroda J, Nogawa M, Yuasa T, Kiyono Y, Wada H, Maekawa T. Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Int J Cancer 2005; 116: 94-99
6. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009; 360: 89-90
7. Cardwell CR, Abnet CC, Cantwell MM, Murray LJ. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 2010; 304: 657-663
8. Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ 2010; 341: c4444
9. Steinbuch M, D"Agostino RB, Mandel JS, Gabrielson E, McClung MR, Stemhagen A, Hofman A. Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort study. Regul Toxicol Pharmacol 2002; 35: 320-326
10. Abrahamsen B, Eiken P, Eastell R. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009; 360: 1789; author reply 1791-1792
11. Solomon DH, Patrick A, Brookhart MA. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009; 360: 1789-1790; author reply 1789-1790
12. Nguyen DM, Schwartz J, Richardson P, El-Serag HB. OralOral bisphosphonate prescriptions and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Dig Dis Sci 2010; 55: 3404-3407
13. Rennert G, Pinchev M, Rennert HS, Gruber SB. Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol 2011; 29: 1146-1150
14. Robins HI, Holen KD. More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med 2009; 360: 1790; author reply 1791-1792
15. Abraham SC, Cruz-Correa M, Lee LA, Yardley JH, Wu TT. Alendronate-associated esophageal injury: pathologic and endoscopic features. Mod Pathol 1999; 12: 1152-1157
16. Singh SP, Odze RD. Multinucleated epithelial giant cell changes in esophagitis: a clinicopathologic study of 14 cases. Am J Surg Pathol 1998; 22: 93-99
17. Graham DY, Malaty HM. Alendronate and naproxen are synergistic for development of gastric ulcers. Arch Intern Med 2001; 161: 107-110
18. Graham DY. What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates. Dig Dis Sci 2002; 47: 1665-1678
19. Chow WH, Finkle WD, McLaughlin JK, Frankl H, Ziel HK, Fraumeni JF. The relation of gastroesophageal reflux disease and its treatment to adenocarcinomas of the esophagus and gastric cardia. JAMA 1995; 274: 474-477
20. Lagergren J, Bergström R, Lindgren A, Nyrén O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-831
21. Pera M. Trends in incidence and prevalence of specialized intestinal metaplasia, barrett"s esophagus, and adenocarcinoma of the gastroesophageal junction. World J Surg 2003; 27: 999-1008; discussion 1006-1008
22. Chlebowski RT, Col N. Bisphosphonates and breast cancer prevention. Anticancer Agents Med Chem 2012; 12: 144-150
23. Dixon WG, Solomon DH. Bisphosphonates and esophageal cancer--a pathway through the confusion. Nat Rev Rheumatol 2011; 7: 369-372
24. Sassa S, Okabe H, Nemoto N, Kikuchi H, Kudo H, Sakamoto S. Ibadronate may prevent colorectal carcinogenesis in mice with ulcerative colitis. Anticancer Res 2009; 29: 4615-4619